Intelligent Bio Solutions INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Intelligent Bio Solutions Inc. reported increased net losses and a going concern warning for fiscal year 2025, despite progress in FDA submissions and global market expansion for its fingerprint drug screening system.
NASDAQ
Intelligent Bio Solutions Inc. files an amendment to its annual report on Form 10-K to update the auditor's consent and clarify document incorporation by reference.
NASDAQ
Intelligent Bio Solutions Inc. released its annual 10-K filing, outlining its financial status, operational achievements, and future strategies, including progress on FDA approval and global expansion.